Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Novavax
Sort By
Newest First
1 / 1
Sign in
1 / 1
Clinical Trials
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax
PR-10-24-NI-48
Oct 17, 2024
COVID-19 Vaccine
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Novavax
PR-M06-21-028
Jun 22, 2021
COVID-19 Vaccine
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Novavax
PR-M05-21-001
May 03, 2021
Fast Track
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
Novavax
PR-M11-20-008
Nov 10, 2020
COVID-19
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India
Novavax
PR-M09-20-NI-17
Sep 15, 2020
Collaboration
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
Novavax
PR-M08-20-NI-19
Aug 13, 2020
Funding
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
Novavax
PR-M07-20-NI-006
Jul 07, 2020
Partnership
Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
AGC Biologics
PR-M06-20-NI-008
Jun 05, 2020
COVID-19 Vaccine
Novavax Expands Large-Scale Global Manufacturing Capacity for COVID-19 Vaccine
Novavax
PR-M05-20-NI-043
May 29, 2020
Strategic Partnership
Novavax and Catalent Biologics Enter Strategic Partnershipto Expand Gene Therapy Footprint
Catalent Biologics
PR-M07-19-NI-001
Jul 01, 2019
